High-cost treatments: resources are not infinite
DOI:
https://doi.org/10.51987/rev.hosp.ital.b.aires.v44i3.395Keywords:
high-cost drug, controversy, commentAbstract
Commentary on a controversial topic such as the administration of high-cost drugs.
Downloads
References
Augustovski F. Evaluaciones económicas en salud I: ¿son válidos los resultados de este estudio? Eviden Aten Primaria. 2002;5(4):123-126. https://doi.org/10.51987/evidencia.v5i4.5309. DOI: https://doi.org/10.51987/evidencia.v5i4.5309
Augustovski F. Evaluaciones económicas en salud II: ¿cuáles son los resultados? ¿Ayudarán en el cuidado de los pacientes? Eviden Aten Primaria. 2002;5(5):154-157. https://doi.org/10.51987/evidencia.v5i5.5295. DOI: https://doi.org/10.51987/evidencia.v5i5.5295
Mauskopf JA, Earnshaw S, Mullins CD. Budget impact analysis: review of the state of the art. Expert Rev Pharmacoecon Outcomes Res. 2005 Feb;5(1):65-79. https://doi.org/10.1586/14737167.5.1.65. DOI: https://doi.org/10.1586/14737167.5.1.65
Trueman P, Drummond M, Hutton J. Developing guidance for budget impact analysis. Pharmacoeconomics. 2001;19(6):609-621. https://doi.org/10.2165/00019053-200119060-00001. DOI: https://doi.org/10.2165/00019053-200119060-00001
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Revista del Hospital Italiano de Buenos Aires

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.










